Q Biomed Inc.

58 articles with Q Biomed Inc.

• Q BioMed Advances QBM-001 for the Treatment of Autism Spectrum Disorder Subtype

  6/4/2019

   Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotechnology acceleration company, today announced advancements on several fronts for its key asset, QBM-001, in the treatment of pediatric minimally verbal autism (PMVA), a rare autism spectrum disorder (ASD) for which no effective treatment currently exists.

• Biotechnology Accelerator, Q BioMed Inc., Selects 5W Public Relations as Agency of Record

  5/30/2019

  Q BioMed Inc. invests strategic capital into undervalued biotech assets and collaborates with passionate scientists to advance promising therapeutics for the benefit of patients in need.

• In a Major Breakthrough Q BioMed Discovers First Biomarkers for Pediatric Nonverbal Autism Subgroup

  4/10/2019

  Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today the discovery of two novel biomarkers for pediatric nonverbal autism, identified in a subset of children with Autism Spectrum Disorder (ASD).

• Q BioMed's Diagnostic Kit Designed to Serve Unmet Need for 70 Million Glaucoma Sufferers

  3/20/2019

  Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced that it has released a new Company Spotlight article on high profile biomedical company Q BioMed Inc..

• Q Biomed's Set to Transform Multi-Billion Dollar Glaucoma Market

  3/12/2019

  Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has released a new Company Spotlight article on high profile biomedical company Q Biomed Inc.

• Q BioMed Licenses Novel Biomarker for Monitoring Glaucoma Severity and Progression from Washington University

  3/11/2019

  Groundbreaking GDF15 biomarker may be the first single examination to accurately predict disease progression

• Q BioMed Responds to OTC Markets Request for Clarity on Investor Awareness Activity

  2/7/2019

  Q BioMed Inc., is providing this response at the request of the OTC markets inquiry into recent expanded investor awareness activities undertaken by the Company.

• Q BioMed to Present at 2019 BIO CEO & Investor Conference

  2/1/2019

  Q BioMed Inc. announced the Company's CEO Denis Corin will deliver a corporate presentation and conduct one-on-one meetings with investors and potential business partners at the BIO CEO & Investor Conference on February 11th -12th, 2019 in New York City.

• Q BioMed Technology Partner Mannin Research Enters Into Collaboration With McMaster University for Glaucoma Drug Candidate MAN-01

  1/25/2019

  Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration company, announced today that its technology partner, Mannin Research, has initiated a collaboration with McMaster University of Ontario, Canada.

• 

  BioSpace Movers and Shakers: Jan. 18

  1/18/2019

  Pharma and biotech companies make changes to their board and leadership teams to advance pipelines and strategies, at SQZ, AstraZeneca, Bioasis, and more.

• Q BioMed Adds Clinical Psychologist at Yale's Child Study Center, Dr. Pamela Ventola to Advisory Committee for QBM-001

  1/16/2019

  Strategy and Clinical Trial Design Specialist Provides Expertise for the Clinical Trial Design and Regulatory Requirements of QBM-001

• Q BioMed Inc Provides Shareholder Update

  1/8/2019

  Company Highlights Recent Achievements and Looks Toward an Active Milestone Rich 2019

• Q BioMed Announces Strategic Partnership With SRI International for Formulation and Preclinical Development of QBM-001 for Pediatric Nonverbal Disorder in Autistic Children

  12/12/2018

  Q Biomed Inc. (OTCQB: QBIO), a biotechnology acceleration company, is pleased to announce a collaborative agreement with SRI International to provide formulation development, preclinical development, and early clinical manufacturing of QBM-001, in support of Q BioMed's Autistic Spectrum Disorder (ASD) drug development program for non-verbal or minimally verbal autistic children.

• Q BioMed Inc Announces Acquisition of Cancer Pain Drug Metastron™ from GE Healthcare

  11/28/2018

  Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration company, is pleased to announce that it has entered into agreement to acquire the metastatic skeletal cancer palliation drug, Metastron™, from GE Healthcare.

• Q BioMed Takes the Stage in the Expanded Access Debate at European Early and Managed Access Program Conference

  10/26/2018

  Q BioMed Orphan Drug VP, who started the first Expanded Access Program Database asked to Speak on Panels and run Roundtable at the Early and Managed Access Program Conference in the UK from October 22nd to 24th 2018

• Q BioMed Provides Important Update on QBM001 Developmental Drug Targeting a Non-Verbal and Minimally Verbal Patient Subset on the Autism Spectrum

  10/9/2018

  Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration company, is pleased to provide an update on QBM001, its Autistic Spectrum Disorder (ASD) drug development program for non-verbal or minimally verbal autistic children.

• 

  BioSpace Movers and Shakers Sept. 24

  9/24/2018

  Here's a look at who's making moves in the biotech and pharma world this week.

• Q Biomed Inc. Announces Dr. Rajendra Apte Joins Advisory Board

  9/17/2018

  Distinguished Ophthalmology Specialist Brings Wealth of Experience

• Q BioMed Inc. Announces FDA Filing for Strontium Chloride Sr89 Injection USP for Relief of Metastatic Cancer Bone Pain

  8/20/2018

  Prior Approval Supplement Filing Under GDUFA Guidelines is Final Step in Approval Process

• Q Biomed Inc. Extends its Exclusive Option Agreement With Washington University in St. Louis for a Novel Companion Biomarker for Monitoring Glaucoma and Initiates a Clinical Study

  7/25/2018

  Q BioMed Inc. is pleased to announce that it is extending its option agreement with Washington University in St. Louis.